| Literature DB >> 33603015 |
Soo Hyun Cho1,2, Sookyoung Woo3, Changsoo Kim4, Hee Jin Kim1,5, Hyemin Jang1,5, Byeong C Kim2, Si Eun Kim6, Seung Joo Kim7, Jun Pyo Kim1, Young Hee Jung8, Samuel Lockhart9, Rik Ossenkoppele10, Susan Landau11, Duk L Na1,5,12, Michael Weiner13, Seonwoo Kim14, Sang Won Seo15,16,17,18,19.
Abstract
To characterize the course of Alzheimer's disease (AD) over a longer time interval, we aimed to construct a disease course model for the entire span of the disease using two separate cohorts ranging from preclinical AD to AD dementia. We modelled the progression course of 436 patients with AD continuum and investigated the effects of apolipoprotein E ε4 (APOE ε4) and sex on disease progression. To develop a model of progression from preclinical AD to AD dementia, we estimated Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-cog 13) scores. When calculated as the median of ADAS-cog 13 scores for each cohort, the estimated time from preclinical AD to MCI due to AD was 7.8 years and preclinical AD to AD dementia was 15.2 years. ADAS-cog 13 scores deteriorated most rapidly in women APOE ε4 carriers and most slowly in men APOE ε4 non-carriers (p < 0.001). Our results suggest that disease progression modelling from preclinical AD to AD dementia may help clinicians to estimate where patients are in the disease course and provide information on variation in the disease course by sex and APOE ε4 status.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33603015 PMCID： PMC7893024 DOI： 10.1038/s41598-021-83585-3
Source DB: PubMed Journal: Sci Rep ISSN： 2045-2322 Impact factor: 4.379